Form 4: CEL SCI Director Robert Watson Granted Stock Options

CEL SCI Corporation's Director and 10% owner, Robert Eugene Watson, was granted 4,000 stock options with an exercise price of $8.20, vesting over three years.

Summary

• Robert Eugene Watson, a Director and 10% owner of CEL SCI Corp (CVM), was granted 4,000 stock options.
• The options have an exercise price of $8.20 per share.
• The options were granted on July 28, 2025, and expire on July 27, 2035.
• The options will vest in three equal annual installments, starting one year after the grant date.
• Following this transaction, Robert Watson beneficially owns 27,266 derivative securities (options).

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a positive sign of continued alignment between management and shareholder interests, though it is a routine compensation event.

Positives

• Grant of stock options to a director aligns their interests with long-term shareholder value.

Future Outlook

The stock options are structured to vest in three equal annual installments, commencing one year after the grant date, indicating a long-term incentive for the director.

Industry Context

Granting stock options to directors is a common practice in the biotechnology and pharmaceutical industry to incentivize long-term commitment and align leadership interests with shareholder returns, especially for companies like CEL SCI which are often in development stages.

Comparison to Industry Standards

• The grant of 4,000 options to a director is a standard form of non-cash compensation, comparable to practices at other small to mid-cap biotech firms.
• The exercise price of $8.20 suggests the options were granted at or above the market price on the grant date, which is typical for incentive options.

Related Party Transactions

• Grant of 4,000 stock options to Robert Eugene Watson, a Director and 10% owner of CEL SCI Corp, as part of his compensation.

Stakeholder Impact

• Shareholders: Potential long-term alignment of director's interests with shareholder value.

Next Steps

• Future vesting of the 4,000 stock options in three equal annual installments, commencing one year after the grant date of July 28, 2025.

Key Dates

Recommendation

This Form 4 filing reports a routine grant of stock options to a director as part of their compensation. While it indicates continued alignment of interests, it does not present new material information that would significantly alter the investment thesis for CEL SCI Corp. Therefore, a "hold" recommendation is appropriate as this filing alone does not warrant a change in investment strategy.

Keywords

CEL SCI, CVM, stock options, insider transaction, Form 4, beneficial ownership, director compensation